Synopsis: The Agreement amends the parties' basic agreement to: add 3,400 sq. ft. of property to be used on an exclusive basis; and increase rent accordingly.

By Order of the Federal Maritime Commission.

Dated: March 11, 1991.

Joseph C. Polking,

Secretary.

[FR Doc. 91-6029 Filed 3-13-91; 8:45 am]

BILLING CODE 6730-01-M

FEDERAL RESERVE SYSTEM

C&S/Sovran Financial Corporation; Acquisition of Company Engaged in Nonbanking Activities

The organization listed in this notice has applied under § 225.23(a) or (f) of the Board's Regulation Y (12 CFR 225.23(a) or (f)) for the Board's approval under section 4(c)(8) of the Bank Holding Company Act (12 U.S.C. 1843(c)(8)) and § 225.21(a) of Regulation Y (12 CFR 225.21(a)) to acquire or control voting securities or assets of a company engaged in a nonbanking activity. Unless otherwise noted, such activities will be conducted throughout the United States.

The application is available for immediate inspection at the Federal Reserve Bank indicated. Once the application has been accepted for processing, it will also be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the question whether consummation of the proposal can "reasonably be expected to produce benefits to the public, such as greater convenience, increased competition, or gains in efficiency, that outweigh possible adverse effects, such as undue concentration of resources, decreased or unfair competition, conflicts of interests, or unsound banking practices." Any request for a hearing on this question must be accompanied by a statement of the reasons a written presentation would not suffice in lieu of a hearing, identifying specifically any questions of fact that are in dispute, summarizing the evidence that would be presented at a hearing, and indicating how the party commenting would be aggrieved by approval of the proposal.

Comments regarding the application must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than April 2, 1991.

A. Federal Reserve Bank of Atlanta (Robert E. Heck, Vice President) 104 Marietta Street, N.W., Atlanta, Georgia 30303:

1. C&S/Sovran Financial Corporation, Norfolk, Virginia; to engage *de novo* through its subsidiary, Sovran Investment Corporation, Norfolk, Virginia, in (1) providing to both its retail and institutional brokerage customers, investment advice in connection with the purchase and sale for the customer's account of a broad range of securities in the secondary market, as well as shares of mutual funds and interests in unit investment trusts; (2) providing brokerage services, but not investment advice, to customers regarding the purchase and sale of shares of investment companies advised by an affiliated bank; (3) providing discretionary investment management services to its institutional customers. These activities have been approved by Board order. *J.P. Morgan & Co.*, 73 Federal Reserve Bulletin 810 (1987); *Bank of New England Corporation*, 74 Federal Reserve Bulletin 700 (1988); *PNC Financial Corp*, 75 Federal Reserve Bulletin 396 (1989). These activities will be conducted worldwide.

Board of Governors of the Federal Reserve System, March 8, 1991.

Jennifer J. Johnson,

Associate Secretary of the Board.

[FR Doc. 91-6030 Filed 3-13-91; 8:45 am]

BILLING CODE 6210-01-F

First Bancorp, Inc.; Acquisition of Company Engaged in Permissible Nonbanking Activities

The organization listed in this notice has applied under § 225.23(a)(2) or (f) of the Board's Regulation Y (12 CFR 225.23(a)(2) or (f)) for the Board's approval under section 4(c)(8) of the Bank Holding Company Act (12 U.S.C. 1843(c)(8)) and § 225.21(a) of Regulation Y (12 CFR 225.21(a)) to acquire or control voting securities or assets of a company engaged in a nonbanking activity that is listed in § 225.25 of Regulation Y as closely related to banking and permissible for bank holding companies. Unless otherwise noted, such activities will be conducted throughout the United States.

The application is available for immediate inspection at the Federal Reserve Bank indicated. Once the application has been accepted for processing, it will also be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the question whether consummation of the proposal can "reasonably be expected to produce benefits to the public, such as greater convenience, increased competition, or gains in efficiency, that outweigh possible adverse effects, such as undue concentration of resources, decreased or unfair competition, conflicts of interests, or unsound banking practices." Any request for a hearing on this question must be accompanied by a statement of the reasons a written presentation would not suffice in lieu of a hearing, identifying specifically any questions of fact that are in dispute, summarizing the evidence that would be presented at a hearing, and indicating how the party commenting would be aggrieved by approval of the proposal.

Comments regarding the application must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than April 2, 1991.

A. Federal Reserve Bank of Minneapolis (James M. Lyon, Vice President) 250 Marquette Avenue, Minneapolis, Minnesota 55480:

1. First Bancorp, Inc., Huron, South Dakota; to acquire the assets of Stapp Insurance Agency, Newell, South Dakota, and Brunner Insurance Agency, Nisland, South Dakota, pursuant to section 4(c)(8)(D) of the Bank Holding Company Act. Applicant currently operates insurance agency pursuant to § 4(a)(2) of the Bank Holding Company Act and has requested that the Board review its right to acquire insurance agencies pursuant to § 4(c)(8)(D).

Board of Governors of the Federal Reserve System, March 8, 1991.

Jennifer J. Johnson,

Associate Secretary of the Board.

[FR Doc. 91-6031 Filed 3-13-91; 8:45 am]

BILLING CODE 6210-01-F

George D. Francklow, Jr.; Change in Bank Control Notice; Acquisition of Shares of Banks or Bank Holding Companies

The notificant listed below has applied under the Change in Bank Control Act (12 U.S.C. 1817(j)) and § 225.41 of the Board's Regulation Y (12 CFR 225.41) to acquire a bank or bank holding company. The factors that are considered in acting on notices are set forth in paragraph 7 of the Act (12 U.S.C. 1817(j)(7)).

The notice is available for immediate inspection at the Federal Reserve Bank indicated. Once the notice has been accepted for processing, it will also be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing to the Reserve Bank indicated for the notice or to the offices of the Board of Governors. Comments must be received not later than April 2, 1991.

A. Federal Reserve Bank of Dallas (W. Arthur Tribble, Vice President) 400 South Akard Street, Dallas, Texas 75222:

1. George D. Francklow, Jr., Houston, Texas; to acquire an additional 4.0 percent of the voting shares of Guardian Bancshares, Inc., Houston, Texas, for a total of 12.25 percent and thereby indirectly acquire Guardian Bank of Houston, Houston, Texas.

Board of Governors of the Federal Reserve System, March 8, 1991.

Jennifer J. Johnson,

Associate Secretary of the Board.

[FR Doc. 91-6032 Filed 3-13-91; 8:45 am]

BILLING CODE 6210-01-F

TAG Bancshares, Inc., et al.; Formations of; Acquisitions by; and Mergers of Bank Holding Companies

The companies listed in this notice have applied for the Board's approval under section 3 of the Bank Holding Company Act (12 U.S.C. 1842) and § 225.14 of the Board's Regulation Y (12 CFR 225.14) to become a bank holding company or to acquire a bank or bank holding company. The factors that are considered in acting on the applications are set forth in section 3(c) of the Act (12 U.S.C. 1842(c)).

Each application is available for immediate inspection at the Federal Reserve Bank indicated. Once the application has been accepted for processing, it will also be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing to the Reserve Bank or to the offices of the Board of Governors. Any comment on an application that requests a hearing must include a statement of why a written presentation would not suffice in lieu of a hearing, identifying specifically any questions of fact that are in dispute and summarizing the evidence that would be presented at a hearing.

Unless otherwise noted, comments regarding each of these applications must be received not later than April 2, 1991.

A. Federal Reserve Bank of Atlanta (Robert E. Heck, Vice President) 104 Marietta Street, N.W., Atlanta, Georgia 30303:

1. TAG Bancshares, Inc., Trenton, Georgia; to become a bank holding company by acquiring 100 percent of the voting shares of Citizens Bank & Trust, Inc., Trenton, Georgia.

2. Tennessee Bancorp, Inc., Columbia, Tennessee; to become a bank holding company by acquiring 100 percent of the voting shares of First Federal Savings & Loan Association, Columbia, Tennessee, which is to be converted to a national bank to be known as Tennessee National Bank.

B. Federal Reserve Bank of Chicago (David S. Epstein, Vice President) 230 South LaSalle Street, Chicago, Illinois 60690:

1. First Michigan Bank Corporation, Holland, Michigan; to merge with Northwestern Bank Corporation, East Jordan, Michigan, and thereby indirectly acquire Northwestern State Bank, East Jordan, Michigan.

C. Federal Reserve Bank of St. Louis (Randall C. Sumner, Vice President) 411 Locust Street, St. Louis, Missouri 63166:

1. M & F Bancorp, Inc., Holly Springs, Mississippi; to become a bank holding company by acquiring 100 percent of the voting shares of Merchants & Farmers Bank, Holly Springs, Mississippi.

D. Federal Reserve Bank of Kansas City (Thomas M. Hoenig, Vice President) 925 Grand Avenue, Kansas City, Missouri 64198:

1. BOK Financial Corporation, Tulsa, Oklahoma; to become a bank holding company by acquiring 99.9 percent of the voting shares of Bank of Oklahoma, N.A., Tulsa, Oklahoma.

Board of Governors of the Federal Reserve System, March 8, 1991.

Jennifer J. Johnson,

Associate Secretary of the Board.

[FR Doc. 91-6033 Filed 3-13-91; 8:45 am]

BILLING CODE 6210-01-F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Advisory Committee; Renewal

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) announces the renewal of the Antiviral Drugs Advisory Committee by the Secretary of Heath and Human Services. This notice is issued under the Federal Advisory Committee Act of October 6, 1972 (Pub. L. 92-463 (5 U.S.C. app. 2)).

DATES: Authority for this committee will expire on February 15, 1993, unless the Secretary formally determines that renewal is in the public interest.

FOR FURTHER INFORMATION CONTACT: Richard Schmidt, Committee Management Office (HFA-306), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-443-2765.

Dated: March 7, 1991.

Alan L. Hoeting,

Acting Associate Commissioner for Regulatory Affairs

[FR Doc. 91-6037 Filed 3-14-91; 8:45 am]

BILLING CODE 4160-01-M

[Docket No. 91F-0059]

Huls America, Inc.; Filing of Food Additive Petition

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that Huls America, Inc., has filed a petition proposing that the food additive regulations be amended to provide for the safe use of a synthetic triglyceride mixture as a cocoa butter substitute.

FOR FURTHER INFORMATION CONTACT: Laureen V. Peters, Center for Food Safety and Applied Nutrition (HFF-334), Food and Drug Administration, 200 C St., SW., Washington, DC 20204, 202-426-8950.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (Section 409(b)(5) (21 U.S.C. 348(b)(5))), notice is given that Huls America, Inc., 80 Centennial Ave., P.O. Box 456, Piscataway, NJ 08855-0456, has filed a petition (FAP 7A4025) proposing that the food additive regulations be amended to provide for the safe use of a synthetic triglyceride mixture (CAS Reg. No. 85665-33-4), obtained by reacting fatty acids derived from coconut or palm kernel oil with glycerol, as a cocoa butter substitute.

The potential environmental impact of this action is being reviewed. If the agency finds that an environmental impact statement is not required and this petition results in a regulation, the notice of availability of the agency's finding of no significant impact and the evidence supporting that finding will be published with the regulation in the **Federal Register** in accordance with 21 CFR 25.40(c).

Dated: March 7, 1991.

Fred R. Shank,

Director, Center for Food Safety and Applied Nutrition.

[FR Doc. 91-6038 Filed 3-13-91; 8:45 am]

BILLING CODE 4160-01-M

[Docket No. 91P-0010]

Cottage Cheese Deviating From Identity Standard; Temporary Permit for Market Testing

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that a temporary permit has been issued to Borden, Inc., to market test a product designated as "nonfat cottage cheese" that deviates from the U.S. standards of identity for cottage cheese (21 CFR 133.128), dry curd cottage cheese (21 CFR 133.129), and lowfat cottage cheese (21 CFR 133.131). The purpose of the temporary permit is to allow the applicant to measure consumer acceptance of the product.

DATES: The permit is effective for 15 months, beginning on the date the food is introduced or caused to be introduced into interstate commerce, but not later than June 12, 1991.

FOR FURTHER INFORMATION CONTACT: Shellee A. Davis, Center for Food Safety and Applied Nutrition (HFF-414), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202-485-0343.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 130.17 concerning temporary permits to facilitate market testing of foods deviating from the requirements of the standards of identity promulgated under section 401 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 341), FDA is giving notice that a temporary permit has been issued to Borden, Inc., 180 East Broad St., Columbus, OH 43215.

The permit covers limited interstate marketing tests of a product that deviates from the U.S. standards of identity for cottage cheese (21 CFR 133.128) and lowfat cottage cheese (21 CFR 133.131) in that the milkfat content of the test product is less than 0.5 percent compared to not less than 4.0 percent milkfat in cottage cheese and 0.5 to 2.0 percent milkfat in lowfat cottage cheese. The test product also deviates from the U.S. standard of identity for dry curd cottage cheese (21 CFR 133.129) because of the added dressing. The product meets all requirements of the standards with the exception of these deviations. The purpose of the variation is to offer the consumer a product that is nutritionally equivalent to cottage cheese products with dressing but contains less fat.

For the purpose of this permit, the name of the product is "nonfat cottage cheese." This permit provides for the temporary marketing of a total of 1,500,000 pounds (680,400 kilograms) of the test product. The product will be manufactured at Meadow Gold plants in Greeley, CO 80631; Honolulu, HI 96805; Boise, ID 83707; Champaign, IL 61824; Jackson, MS 39704; Kalispell, MT 55901; Albuquerque, NM 87103; Lincoln, NE 68501; Youngstown, OH 44512; Tulsa, OK 74101; Sulphur Springs, TX 75482; Charleston, WV 25302; and Milwaukee, WI 53214, and distributed in Alabama, Arkansas, Colorado, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Kansas, Kentucky, Louisiana, Maryland, Michigan, Mississippi, Missouri, Montana, Nebraska, Nevada, New Mexico, North Carolina, Ohio, Oklahoma, South Carolina, Texas, Utah, Virginia, West Virginia, and Wisconsin.

Each of the ingredients used in the food must be stated on the label as required by the applicable sections of 21 CFR part 101. This permit is effective for 15 months, beginning on the date the food is introduced or caused to be introduced into interstate commerce, but not later than June 12, 1991.

Dated: March 6, 1991.

Fred R. Shank,

Director, Center for Food Safety and Applied Nutrition.

[FR Doc. 91-6039 Filed 3-13-91; 8:45 am]

BILLING CODE 4160-01-M

[Docket No. 91N-0085]

Wyeth-Ayerst Laboratories, Inc.; Withdrawal of Approval of Portions of Two New Drug Applications for Phenergan

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is withdrawing approval of those portions of two new drug applications (NDA's) that provide for the over-the-counter (OTC) marketing of two Phenergan Syrup products. This action is based on the written request of Wyeth-Ayerst Laboratories, Inc., P.O. Box 8299, Philadelphia, PA 19101.

EFFECTIVE DATE: April 15, 1991.

FOR FURTHER INFORMATION CONTACT: Douglas I. Ellsworth, Center for Drug Evaluation and Research (HFD-366), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-295-8041.

SUPPLEMENTARY INFORMATION: Wyeth-Ayerst Laboratories, Inc. (Wyeth), holds approved NDA's that provide for prescription marketing of the following promethazine-containing combination drug products:

NDA 8-604 for Phenergan VC Syrup containing phenylephrine hydrochloride and promethazine hydrochloride.

NDA 11-265 for Phenergan with Dextromethorphan Syrup containing dextromethorphan hydrobromide and promethazine hydrochloride.

On August 11, 1988, FDA approved supplemental NDA's to NDA's 8-604 and 11-265 that provide for the OTC labeling and marketing of Phenergan VC Syrup and Phenergan DM Syrup (the same as Phenergan with Dextromethorphan Syrup).

Promethazine-containing combination drug products are also under review in the agency's OTC Drug Review (Docket No. 76N-052G). Under the OTC Drug Review, a citizen petition and comments have been filed expressing concerns about the safety of the OTC marketing of promethazine-containing products. This issue is currently under review by the agency.

Because of these concerns, Wyeth has requested that FDA withdraw approval of those portions of NDA's 8-604 and 11-265 that provide for the OTC labeling and marketing of Phenergan VC Syrup and Phenergan DM Syrup. Wyeth notes that the issues concerning the OTC marketing of promethazine-containing products are best resolved solely in the public forum provided by the agency's OTC Drug Review monograph process.

Accordingly, under section 505(e) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(e)) and under authority delegated to the Director of the Center for Drug Evaluation and Research (21 CFR 5.82), approval of those portions of NDA's 8-604 and 11-265 that provide for the OTC marketing of Phenergan VC Syrup and Phenergan DM Syrup, and all amendments and supplements thereto, is hereby withdrawn, effective April 15, 1991. This withdrawal of approval does not affect the prescription promethazine-containing products covered by NDA's 8-604 and 11-265.

Dated: March 6, 1991.

Carl C. Peck,

Director, Center for Drug Evaluation and Research.

[FR Doc. 91-6041 Filed 3-13-91; 8:45 am]

BILLING CODE 4160-01-M

Advisory Committees; Meetings

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: This notice announces forthcoming meetings of public advisory committees of the Food and Drug